Dec 11 (Reuters) - ADC Therapeutics ADCT.N:
ADC THERAPEUTICS ANNOUNCES POSITIVE INITIAL DATA FROM LOTIS-7 CLINICAL TRIAL EVALUATING ZYNLONTA® IN COMBINATION WITH BISPECIFIC ANTIBODY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
ADC THERAPEUTICS SA - ZYNLONTA PLUS GLOFITAMAB SHOWS 94% ORR AND 72% CR RATE
ADC THERAPEUTICS SA - NO DOSE-LIMITING TOXICITIES OR HIGH-GRADE CRS/ICANS OBSERVED
Source text: ID:nPn7x6p8Ma
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.